South Africa Receives First Shipment of Revolutionary HIV Prevention Drug in Major Public Health Breakthrough
Pretoria, South Africa – April 7, 2025
South Africa has taken a monumental step forward in the fight against HIV/AIDS with the arrival of the first shipment of Lenacapavir, a groundbreaking twice-yearly injectable prevention medication. The U.S. Mission to South Africa hailed the delivery as a turning point in global health collaboration, marking the first time the revolutionary drug has been made available in Africa.
The shipment, consisting of 37,920 doses, was cleared for distribution following approval by the South African Health Products Regulatory Authority (SAHPRA) in October 2025. South Africa is now the first country on the continent to authorize the use of Lenacapavir, which promises to transform HIV prevention by replacing daily oral medications with a more manageable twice-a-year injection.
A Milestone in HIV Prevention
Lenacapavir, developed by U.S.-based biotech firm Gilead Sciences, has been hailed as a game-changer for at-risk populations, particularly in regions with high HIV prevalence. Unlike daily pre-exposure prophylaxis (PrEP) pills, which require strict adherence, the new injectable offers a simpler, more discreet alternative—significantly improving the likelihood of consistent use.
“This is a historic moment for South Africa and the global HIV response,” said U.S. Ambassador L. Brent Bozell III. “Through American innovation and strong partnerships, we are bringing life-saving solutions to those who need them most.”
The U.S. has been a key supporter of the initiative, contributing over $28 billion to the Global Fund to Fight AIDS, Tuberculosis, and Malaria—the largest commitment by any nation. An additional $4.6 billion has been pledged for the fund’s Eighth Replenishment, reinforcing America’s long-standing role in advancing global health security.
How Public-Private Collaboration Made It Possible
The successful rollout of Lenacapavir in South Africa underscores the power of international cooperation. Gilead Sciences worked closely with the Global Fund, SAHPRA, and South Africa’s National Department of Health to fast-track regulatory approval and ensure swift distribution.
Public health experts say the drug’s introduction could be particularly impactful in South Africa, which has one of the highest HIV burdens in the world. With more than 7.5 million people living with HIV, the country has been at the forefront of prevention and treatment efforts, including widespread antiretroviral therapy (ART) programs.
“Lenacapavir isn’t just another treatment—it’s a paradigm shift,” said Dr. Thandiwe Nkosi, a Johannesburg-based HIV specialist. “For young women, migrant workers, and others who struggle with daily pill regimens, this could be the key to drastically reducing new infections.”
What’s Next for HIV Prevention in Africa?
While the initial shipment is a major victory, health officials emphasize that scaling up access remains a priority. Advocacy groups are calling for affordable pricing and expanded distribution to neighboring countries with high HIV rates.
The U.S. Mission has pledged ongoing support, signaling deeper collaboration with South African authorities and global health organizations to expand access to cutting-edge treatments. As Lenacapavir rolls out, the focus will shift to education campaigns ensuring communities understand its benefits and how to access it.
For now, the arrival of the drug in South Africa stands as a testament to what can be achieved when governments, private companies, and global health advocates unite behind a common goal—ending the HIV epidemic once and for all.
— Reported by Nexio News
